Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Minoxidil

FDA-approved product (tablet, oral), marketed as Loniten, Men's Rogaine, Minodyl and 9 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Minoxidil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alopecia
  • Androgenetic alopecia
  • Hypertension
  • Hypotrichosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pyrimidine derivatives; Other dermatologicals
FDA pharmacologic class
Arteriolar Vasodilator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Minoxidil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Minoxidil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

    NCT05272462 · start 2021-12-13

    Registered record
    Registry ID
    NCT05272462
    Conditions
    Ovarian Cancer
    Interventions
    Minoxidil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-12-13
    Completion
    2024-12-31
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionMinoxidil
    PhasePhase 2
    Registry statusUnknown

  • Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

    NCT05296863 · start 2021-10-11

    Registered record
    Registry ID
    NCT05296863
    Conditions
    Alopecia, Androgenetic; Hair Loss/Baldness
    Interventions
    Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil; Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil; Placebo and 5% Minoxidil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-10-11
    Completion
    2021-12-03
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia, Androgenetic; Hair Loss/Baldness
    InterventionNon-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil; Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil; Placebo and 5% Minoxidil
    PhasePhase 3
    Registry statusCompleted

  • Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia

    NCT04293822 · start 2020-06

    Registered record
    Registry ID
    NCT04293822
    Conditions
    Androgenetic Alopecia
    Interventions
    Cetirizine; Minoxidil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-06
    Completion
    2021-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenetic Alopecia
    InterventionCetirizine; Minoxidil
    PhasePhase 4
    Registry statusUnknown

  • Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

    NCT03831334 · start 2019-04-09

    Registered record
    Registry ID
    NCT03831334
    Conditions
    Permanent Chemotherapy-induced Alopecia
    Interventions
    oral minoxidil
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2019-04-09
    Completion
    2026-08
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPermanent Chemotherapy-induced Alopecia
    Interventionoral minoxidil
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • N-Acetyl-Cysteine for Treatment of AGA in Men

    NCT04209803 · start 2018-12-01

    Registered record
    Registry ID
    NCT04209803
    Conditions
    Androgenetic Alopecia
    Interventions
    Minoxidil 5% topically and oral NAC 600 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-12-01
    Completion
    2020-10-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenetic Alopecia
    InterventionMinoxidil 5% topically and oral NAC 600 mg
    PhasePhase 4
    Registry statusCompleted

  • Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure

    NCT03528772 · start 2018-05-10

    Registered record
    Registry ID
    NCT03528772
    Conditions
    Anal Fissure
    Interventions
    Minoxidil; Glyceryl trinitrate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-05-10
    Completion
    2019-09-30
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Fissure
    InterventionMinoxidil; Glyceryl trinitrate
    PhaseNot applicable
    Registry statusCompleted

  • Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

    NCT03488108 · start 2017-01-23

    Registered record
    Registry ID
    NCT03488108
    Conditions
    Alopecia
    Interventions
    Platelet Rich Plasma; Minoxidil Foam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-01-23
    Completion
    2019-06-17
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia
    InterventionPlatelet Rich Plasma; Minoxidil Foam
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

    NCT02483195 · start 2016-08

    Registered record
    Registry ID
    NCT02483195
    Conditions
    Female Androgenetic Alopecia
    Interventions
    5% Minoxidil; 200mg Spironolactone; 5mg Finasteride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-08
    Completion
    2018-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemale Androgenetic Alopecia
    Intervention5% Minoxidil; 200mg Spironolactone; 5mg Finasteride; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia

    NCT02824380 · start 2016-07

    Registered record
    Registry ID
    NCT02824380
    Conditions
    Androgenic Alopecia
    Interventions
    DA-4001 H; DA-4001 L
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-07
    Completion
    2016-10
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenic Alopecia
    InterventionDA-4001 H; DA-4001 L
    PhasePhase 1
    Registry statusCompleted

  • Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata

    NCT03535233 · start 2016-03

    Registered record
    Registry ID
    NCT03535233
    Conditions
    Alopecia Areata
    Interventions
    Triamcinolone Acetonide; Minoxidil 5 % Topical Spray; clobetasol propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-03
    Completion
    2017-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata
    InterventionTriamcinolone Acetonide; Minoxidil 5 % Topical Spray; clobetasol propionate
    PhasePhase 4
    Registry statusCompleted

  • Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia

    NCT02460497 · start 2015-05-27

    Registered record
    Registry ID
    NCT02460497
    Conditions
    Female Pattern Hair Loss, Androgenic Alopecia
    Interventions
    Treatment: Minoxidil 2% / Botanical Hair Solution for Women
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-05-27
    Completion
    2015-09-19
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemale Pattern Hair Loss, Androgenic Alopecia
    InterventionTreatment: Minoxidil 2% / Botanical Hair Solution for Women
    PhaseNot applicable
    Registry statusCompleted

  • Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia

    NCT02460289 · start 2015-05-19

    Registered record
    Registry ID
    NCT02460289
    Conditions
    Male Pattern of Hair Loss, Androgenic Alopecia
    Interventions
    Treatment: Minoxidil 5% / Botanical Hair Solution for Men
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-05-19
    Completion
    2015-11
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Pattern of Hair Loss, Androgenic Alopecia
    InterventionTreatment: Minoxidil 5% / Botanical Hair Solution for Men
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement

    NCT02283645 · start 2015-01

    Registered record
    Registry ID
    NCT02283645
    Conditions
    Chest Hair Enhancement
    Interventions
    3 % minoxidil lotion; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2015-08
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChest Hair Enhancement
    Intervention3 % minoxidil lotion; Placebo
    PhasePhase 4
    Registry statusUnknown

  • A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

    NCT02279823 · start 2014-10

    Registered record
    Registry ID
    NCT02279823
    Conditions
    Androgenetic Alopecia
    Interventions
    CB-03-01 solution; Minoxidil Solution 5%; Placebo solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-05
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenetic Alopecia
    InterventionCB-03-01 solution; Minoxidil Solution 5%; Placebo solution
    PhasePhase 2
    Registry statusCompleted

  • Minoxidil Response Testing in Females With Female Pattern Hair Loss

    NCT02206802 · start 2014-07

    Registered record
    Registry ID
    NCT02206802
    Conditions
    Alopecia; Female Pattern Hair Loss
    Interventions
    5% minoxidil topical foam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-07
    Completion
    2018-10
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia; Female Pattern Hair Loss
    Intervention5% minoxidil topical foam
    PhaseNot recorded
    Registry statusCompleted